RCS - Hutchmed China Ltd - Publication of Form 20-F

HUTCHMED (China)Announcement

03/03/2022 15:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220303:nRSC5788Da&default-theme=true

RNS Number : 5788D  Hutchmed (China) Limited  03 March 2022

 

 

Press Release

 

Publication of Form 20-F

 

 

Hong Kong, Shanghai & Florham Park, NJ: Thursday, March 3, 2022: HUTCHMED
(China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today published the
Form 20-F for the financial year ended December 31, 2021.  This is available
for viewing at
http://www.rns-pdf.londonstockexchange.com/rns/5788D_1-2022-3-3.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/5788D_1-2022-3-3.pdf) and also
on the website of the Company at www.hutch-med.com
(https://www.hutch-med.com/) .

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery, global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has more than 4,600
personnel across all its companies, at the center of which is a team of over
1,500 in oncology/immunology. Since inception it has advanced 12 cancer drug
candidates from in-house discovery into clinical studies around the world,
with its first three oncology drugs now approved and marketed in China. For
more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

CONTACTS

 Investor Enquiries
 Mark Lee, Senior Vice President                                  +852 2121 8200
 Annie Cheng, Vice President                                      +1 (973) 567 3786

 Media Enquiries
 Americas - Brad Miles, Solebury Trout                            +1 (917) 570 7340 (Mobile)

bmiles@troutgroup.com
 Europe - Ben Atwell / Alex Shaw, FTI Consulting                  +44 20 3727 1030 / +44 7771 913 902 (Mobile) /
                                                                  +44 7779 545 055 (Mobile)

HUTCHMED@fticonsulting.com (mailto:hutchmed@fticonsulting.com)
 Asia - Zhou Yi, Brunswick                                        +852 9783 6894 (Mobile)

HUTCHMED@brunswickgroup.com

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley, Panmure Gordon (UK) Limited    +44 (20) 7886 2500

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABKNBKPBKDANK